Brain dopamine receptors - Research perspectives and potential sites of regulation

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 659-671

  Dziedzicka Wasylewska, Marta ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

D1 D2 synergism; Dopamine receptor gene polymorphism; Dopamine receptor kinases; Dopamine receptors; Receptor dimerization

Indexed keywords

ADENYLATE CYCLASE; ALANINE; CALCIUM; CYCLIC AMP; CYSTEINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 6; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL 1,4,5 TRISPHOSPHATE; MEMBRANE RECEPTOR; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; OXIDOPAMINE; PROLINE; PROTEIN TYROSINE KINASE; RETINA S ANTIGEN; SERINE; VALINE;

ADDICTION; AMINO ACID SUBSTITUTION; CALCIUM CELL LEVEL; CELL INTERACTION; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME POLYMORPHISM; DELUSION; DIMERIZATION; DNA POLYMORPHISM; DOPAMINE METABOLISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; EXON; GENETIC CODE; HALLUCINATION; HUMAN; HYPOKINESIA; INTRON; LINKAGE ANALYSIS; MOOD DISORDER; NERVE CELL; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; RECEPTORS, DOPAMINE;

EID: 14244256767     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Agnati LF, Ferre S, Lluis C, Franco R, Fuxe K: Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev, 2003, 55, 509-550.
2. 2 dopamine receptor colocalization in neostriatal neurons. Nat Neurosci, 2000, 3, 226-230.
3. Arnt J, Skarsfeldt T: Do novel antipsychotics have similar pharmacological characteristics? A review of evidence. Neuropharmacology 1998, 18, 63-118.
4. 4 receptor repeat: analysis of different native and mutant forms. Mol Pharmacol, 1994, 46, 364-373.
5. Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, Remick RA, Keck PE, McElroy SL et al.: Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol Psychiatry, 2003, 8, 546-557.
6. 2+ connection in dopamine signaling. Trends Pharmacol Sci, 2003, 24, 486-492.
7. Caron MG, Beanhein M, Raymond V, Gagne B, Drouin J, Lefkovitz RJ, Labrie F: Dopaminergic receptors in the anterior pituitary gland. J Biol Chem, 1978, 253, 2244-2253.
8. 4 receptor locus. Hum Genet, 1996, 98, 91-101.
9. Chase TN, Justin D, Blanchet PJ: Neostriatal mechanisms in Parkinson's disease. Neurology, 1998, 51, Suppl 2, S30-S35.
10. Childress AR, O'Brian CP: Dopamine receptor partial agonists address the duality of cocaine craving. Trends Pharmacol Sci, 2000, 21, 6-9.
11. 1 receptor (DRD1) gene in patients with schizophrenia and bipolar disorder. Am J Med Genet, 1996, 67, 424-428.
12. Civelli O, Bunzow JR, Grandy DK: Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol, 1993, 32, 281-307.
13. 2 dopamine receptor in the intermediate lobe of the rat pituitary gland: a review. Neuroendocrinology, 1982, 35, 217-224.
14. 2 dopamine receptor missense variants. J Biol Chem, 1996, 271, 26013-26017.
15. 2 dopamine missense variants. Pharmacogenetics, 1999, 9, 17-23.
16. D'Aquila PS, Collu M, Gessa GL, Serra G: The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol, 2000, 405, 3615-373.
17. Drago J, Padungchaichot P, Accili D, Fuchs S: Dopamine receptors and dopamine transporter in brain function and addictive behaviors: insights from targeted mouse mutants. Dev Neurosci, 1998, 20, 188-203.
18. 3 dopamine receptor gene. J Neurochem, 2001, 76, 1736-1744.
19. Dziedzicka-Wasylewska M, Ferrari F, Johnson RD, Mierau J, Rogóz Z, Skuza G, Sokoloff P: Mechanism of action of pramipexole. Rev Contemp Pharmacother, 2001, 12, 1-31.
20. Emilien G, Maloteaux J-M, Geurts M, Hoogenberg K, Cragg S: Dopamine receptors - physiological understanding to therapeutic intervention potential. Pharmacol Ther, 1999, 84, 133-156.
21. Erdtmann-Vourliotis M, Mayer P, Ammon S, Reichert U, Hollt V: Distribution of G protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res, 2001, 95, 129-137.
22. Fehr C, Fickova M, Hiemke C, Reuss S, Dahmen N: Molecular cloning of rat G protein-coupled receptor kinase 6 (GRK 6) from brain tissue, and its mRNA expression in different brain regions and peripheral tissues. Brain Res Mol Brain Res, 1997, 49, 278-282.
23. Ferguson SSG: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev, 2001, 53, 1-24.
24. Ferguson SSG, Zhang J, Barak LS, Caron MG: Molecular mechanisms of G protein-coupled receptor desensitization and resensitization. Life Sci, 1998, 62, 1561-1565.
25. 1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem, 2003, 278, 20196-20202.
26. Franco R, Ferre S, Agnati I, Torrinen M, Gines S, Hillion J, Casado V et al.: Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology, 2000, 23, Suppl 4, S50-S59.
27. Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, Torres G et al.: Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron, 2003, 38, 291-303.
28. Gainetdinov RR Premont RT, Bohn LM, Lefkowitz RJ, Caron MG: Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci, 2004, 27, 107-144.
29. George SR, Lee SP, Varghose G, Zeman PR, Seeman P, Ng GKY, O'Dowd BF: A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem, 1998, 273, 30244-30248.
30. Gerfen CR: Molecular effects of dopamine on striatal-projection pathways. Trends Neurosci, 2000, 23, Suppl, S64-S70.
31. Gershanik O, Heikkila RE, Duvoisin RC: Behavioral correlation of dopamine receptor activation. Neurology, 1983, 33, 1489-1492.
32. Ginés S. Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, Roudin S et al.: Dopamine D1 and adenosine A1 receptors assemble into functionally interacting heteromeric complexes. Proc Natl Acad Sci USA, 2000, 97, 8606-8611.
33. 3 dopamine receptor produced through various patterns of alternative splicing. Biochem Biophys Res Commun, 1991, 176, 1584-1592.
34. 2 dopamine receptor isoforms. Nature, 1989, 342, 923-926.
35. Goodman AB: Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA, 1998, 95, 7240-7244.
36. Gouldson PR, Snell CR, Bywater RP, Higgs C, Reynolds CA: Domain swapping in G protein-coupled receptor dimmers. Protein Eng, 1998, 11, 1181-1193.
37. 2 receptor gene is located on chromosome 11 at q22-q23 and identifies a Taq I RFLP. Am J Med Genet, 1989, 45, 778-785.
38. 2 dopamine receptor. Proc Natl Acad Sci USA, 1989, 86, 9762-9766.
39. Hall RA, Premont RT, Lefkovitz RJ: Heptahelical receptor signalling: beyond the G protein paradigm. J Cell Biol, 1999, 145, 927-932.
40. Hamm HE, Gilchrist A: Heterotrimeric G proteins. Curr Opin Cell Biol, 1996, 8, 189-196.
41. Herbert TE, Bouvier M: Structural and functional aspects of G protein-coupled receptor oligomerization. Biochem Cell Biol, 1998, 76, 1-11.
42. 1 receptor with adenylyl cyclase. J Neurosci, 1993, 13, 2237-2248.
43. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A et al.: Coaggregation, cointernalization, and codesensitization of adenosine A2A receptor and dopamine D2 receptors. J Biol Chem, 2002, 277, 18091-18097.
44. Hornykiewicz O: Biochemical aspects of Parkinson's disease. Neurology, 1998, 51, Suppl 2, S2-S9.
45. Hyman SE, Malenka RC: Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci, 2001, 2, 695-703.
46. 2 receptors in the nucleus accumbens in mediating reward. J Neurosci, 1997, 17, 8580-8587.
47. Imperato A, Di Chiara G: Effects of locally applied D-1 and D-2 receptor agonists and antagonists studied with brain dialysis. Eur J Pharmacol, 1988, 156, 385-393.
48. 2 receptors depends on coexpression of G protein-coupled receptor kinases 2 and 5. Eur J Biochem, 1999, 260, 112-119.
49. 2 receptor. Eur J Biochem, 1999, 263, 596-602.
50. Jaber M, Robinson SW, Missale C, Caron MG: Dopamine receptors and brain function. Neuropharmacology, 1996, 35, 1503-1519.
51. Jackson DM, Westlind-Danielsson A: Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther, 1994, 64, 291-369.
52. Jenner P, Marsden CD: Chronic pharmacological manipulation of dopamine receptor in the brain. Neuropharmacology, 1987, 26, 931-940.
53. 2 receptor gene. Neuropharmacology, 1998, 37, 803-814.
54. 4.10 receptor variants. Pharmacogenetics, 1999, 9, 561-568.
55. 2 dopamine receptor. J Neurosci, 2002, 22, 8476-8486.
56. Kebabian JW, Petzgold GL, Greengard P: Dopamine-sensitive adenylate cyclase in caudate nucleus of rat brain and its similarity to the "dopamine receptor". Proc Natl Acad Sci USA, 1972, 69, 2145-2149.
57. 2 short isoform in dopamine pathways. Proc Natl Acad Sci USA, 1998, 95, 7731-7736.
58. 3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem, 2001, 276, 37409-37414.
59. Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic P, Lidow MS: Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci USA, 2003, 100, 13-17.
60. Laakso A, Mohn AR, Gainetdinov RR, Caron MG: Experimental genetic approaches to addiction. Neuron, 2002, 36, 213-228.
61. La Hoste GJ, Marshall JF: New concepts in dopamine receptor plasticity. Ann NY Acad Sci, 1993, 702, 183-196.
62. La Hoste GJ, Marshall JF: The role of dopamine in the maintenance and breakdown of D1/D2 synergism. Brain Res, 1993, 611, 108-116.
63. La Hoste GJ, Yu J, Marshall JF: Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity. Proc Natl Acad Sci USA, 1993, 90, 7451-7455.
64. La Hoste GJ, Marshall JF: Dopamine receptor interactions in the brain. In: CNS Neurotransmitters and Neuromodulators: Dopamine. Ed. Stone TW, CRC Press Inc, Boca Raton, Florida, 1996, 107-119.
65. 1 receptor. J Biol Chem, 2002, 277, 9415-9421.
66. Lavine N, Ethier N, Oak JN, Pei L, Liu F, Trien P, Rebois RV et al.: G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem, 2002, 277, 46010-46019.
67. Le Moal M, Simon H: Mesolimbic dopaminergic network: functional and regulatory roles. Physiol Rev, 1991, 71, 155-234.
68. Lewis MH, Widerlov E, Knight DL, Kilts CD, Mailman RB: N-Oxides of phenotiazine antipsychotics: effects on in vivo and in vitro estimates of dopaminergic functions. J Pharmacol Exp Ther, 1983, 225, 539-545.
69. 1 receptor interacting protein. Science, 2000, 287, 1660-1664.
70. 1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Am J Med Genet, 1995, 60, 165-171.
71. Liu F, Wan Q, Pristupa ZB, Yu XM, Wang YT, Niznik HB: Direct protein-protein coupling enables cross-talk between dopamine D5 and gamma-aminobutyric acid A receptors. Nature, 2000, 403, 274-280.
72. 3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun, 1996, 225, 1068-1072.
73. Luttrell LM, Lefkowitz RJ: The role of beta-arrestins in the termination and transduction of G protein-coupled receptor signals. J Cell Sci, 2002, 115, 455-465.
74. 2 behavioral actions. Eur J Pharmacol, 1984, 101, 159-160.
75. 2 receptor isoforms in various cerebral tissues. J Neurochem, 1992, 58, 673-678.
76. Marzadegan T, Benko G, Filipek S, Palczewski K: Sequence analyses of G protein-coupled receptors: similarities to rhodopsin. Biochemistry, 2003, 42, 2759-2767.
77. Matsumoto M, Hidaka K, Tada S, Tasaki Y, Yamaguchi T: Full length cDNA cloning and distribution of human dopamine D4 receptor. Brain Res Mol Brain Res, 1995, 29, 157-162.
78. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, Watson SJ: Dopamine receptor mRNA. expression in human striatum and neocortex. Neuropsychopharmacology, 1996, 15, 17-29.
79. Milligan G, White JH: Protein-protein interactions at G protein-coupled receptors. Trends Pharmacol Sci, 2001, 22, 513-518.
80. 2 dopamine receptor gene. Biochemistry, 1992, 31, 8389-8396.
81. Missale CX, Nash SR, Robinson SW, Jabber M, Caron MG: Dopamine receptors: from structure to function. Pharmacol Rev, 1998, 78, 189-225.
82. Neubig RR, Siderovski DP: Regulators of G protein signaling as new central nervous system drug targets. Nat Rev Drug Discov, 2002, 1, 187-197.
83. Ng GYK, O'Dowd BF, Lee SP, Chung HT, Braun MR, Seeman P, George SR: Dopamine D2 receptor dimmers and receptor blocking peptides. Biochem Biophys Res Commun, 1996, 227, 200-204.
84. Nicola SM, Surmeier J, Malenka RC: Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci, 2000, 23, 185-215.
85. Nimchinsky EA, Hof PR, Janssen WGM, Morrison JH, Schmauss C: Expression of dopamine D3 receptor dimers and tetramers in brain and transfected cells. J Biol Chem, 1997, 272, 29229-29237.
86. 4 receptor: one decade of research. Eur J Pharmacol, 2000, 405, 303-327.
87. Pan HS, Engber TM, Chase TN, Walters JR: The effect of striatal lesion on turning behavior and globus pallidus single unit response to dopamine agonist administration. Life Sci, 1990, 46, 73-80.
88. Pei L, Lee FJS, Moszczynska A, Vukusic B, Liu F: Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci, 2004, 24, 1149-1158.
89. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM: Constitutive activation of a single effector pathway: evidence for multiple activation states of G protein-coupled receptor. Mol Pharmacol, 1996, 49, 112-122.
90. Perry SJ, Lefkowitz RJ: Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol, 2002, 12, 130-138.
91. 3 receptor agonist. Nature, 1999, 400, 371-375.
92. 3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. Eur J Neurosci, 1998, 10, 1676-1686.
93. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science, 2000, 289, 154-157.
94. Salim H, Ferre S, Dalal A, Peterfreund RA, Fuxe K, Vincent JD, Lledo PM: Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem, 2000, 74, 432-439.
95. 2 receptor promoters by members of the retinoic acid receptor - retinoid X receptor family. Proc Natl Acad Sci USA, 1997, 94, 14354-14394.
96. Scarselli M, Novi F, Schallmach E, Liu R, Baragli A, Colzi A, Griffon N et al.: D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem, 2001, 276, 30308-30314.
97. Schlessinger J, Urlich A: Growth factor signalling by receptor tyrosine kinases. Neuron, 1992, 9, 383-391.
98. 3 receptor: basic and clinical aspects. Neuropharmacology, 1993, 16, 295-314.
99. Sealfon SC, Olanow CW: Dopamine receptors: from structure to behavior. Trends Neurosci, 2000, 23, Suppl, S34-S40.
100. 5 receptor gene and identification of highly polymorphic microsatelite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics, 1993, 18, 423-425.
101. Sibley DR: New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol, 1999, 39, 313-341.
102. Singer HS: Neurobiological issues in Tourette syndrome. Brain Dev, 1994, 16, 353-364.
103. 3 receptor. Biochem Biophys Res Commun, 1991, 180, 1031-1035.
104. 5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Hum Mol Genet, 1995, 4, 507-514.
105. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterization of a novel dopamine (D3) receptor as a target for neuroleptics. Nature, 1990, 347, 146-151.
106. Stoof JC, Kebabian JW: Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci, 1984, 35, 2281-2296.
107. Surmeier DJ, Eberwine J, Wilson CJ, Stefani A, Kitai ST: Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA, 1992, 89, 10178-10182.
108. Surmeier DJ, Song WJ Yan Z: Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci, 1996, 16, 6579-6591.
109. Tiberi M, Caron MG: High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem, 1994, 269, 27925-27931.
110. Tiberi M, Nash SR, Bertrand L, Lefkowitz RJ, Caron MG: Differential regulation of dopamine D1a responsiveness by various G protein-coupled receptor kinases. J Biol Chem, 1996, 271, 3771-3778.
111. 2 receptors. Nature, 2000, 408, 199-203.
112. 2 receptor. Trends Pharmacol Sci, 1989, 10, 74-77.
113. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 1991, 350, 610-614.
114. 4 receptor variants in the human population. Nature, 1992, 358, 149-152.
115. 2 dopamine agonists in nigrostriatal and meso-accumbens dopamine systems. Synapse, 1989, 4, 327-346.
116. 2 agonist effects. Science, 1987, 236, 719-722.
117. 5 dopamine receptors on the G protein gamma 7 subunit for activation of adenylyl cyclase. J Biol Chem, 2001, 276, 39386-39393.
118. 2 receptors necessary for the expression of dopamine-mediated behaviors? Pharmacol Biochem Behav, 1988, 30, 189-193.
119. Willets JM, Challiss RA, Nahorski SR: Non-visual GRKs: are we seeing the whole picture? Trends Pharmacol Sci, 2002, 24, 626-633.
120. Wong AHC, Buckle C, Van Tol HHM: Polymorphisms in dopamine receptors: what do they tell us? Eur J Pharmacol, 2000, 410, 183-203.
121. Zawarynski P, Tallerico T, Seeman V, Lee SP, O'Dowd BF, George SR: Dopamine D2 receptor dimers in human and rat brain. FEBS Lett, 1998, 441, 383-386.
122. Zhang J, Barak LS, Anborgh PH, Laporte SA, Caron MG, Ferguson SSG: Cellular trafficking of G protein-coupled receptor/β arrestin endocytotic complexes. J Biol Chem, 1999, 274, 10999-11006.
123. 1 dopamine receptors. Nature, 1990, 347, 76-80.
124. 1 receptor gene. J Neurochem, 1992, 59, 1875-1883.